louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05307562: Efficacy of Respiratory Rehabilitation After COVID-19 Severe Infection
Official title: Efficacy of Respiratory Rehabilitation After COVID-19 Severe Infection
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: COVID-19 Respiratory Infection
Rehabilitation
Physical Therapists
Keywords: covid-19
training program
respiratory physiotherapy
Lead sponsor: Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Sponsor class: OTHER
First posted: 2022-04-01
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the effects of a training program in patients that have suffered a COVID infection

Detailed description: Once patients have been selected and meet inclusion criteria, they will sign informed consent. They will make a first visit to obtain the basal parameters. Once done, they will start the individualized training program for 12 weeks 3 times a week.

Eligibility criteria: Inclusion Criteria:

* Men and women ≥18 years
* Patients discharged from the Pulmonology Service with a diagnosis of COVID-19 by positive PCR and with severe pneumonia.
* At least three months after the presence of at least one of the following criteria:

  1. MRC dyspnea greater than or equal to 2.
  2. Decrease in the meters walked with respect to the reference values in the 6-minute walking test.

     C) Decreased respiratory muscle strength measured at Maximum Inspiratory Pressure (PIM) and / or Maximum Expiratory Pressure (PEM) with respect to reference values.
* Sign informed consent from the study

Exclusion Criteria:

* Patients who do not want to be included in the study.
* Pregnant women.
* Impossibility to perform ergometry or ultrasound.

Primary outcomes:
measure: changes in walking distance in the 6 minutes walk test
timeFrame: Baseline and 12 weeks after
Secondary outcomes:
measure: changes in the maximum watts generated
timeFrame: Baseline and 12 weeks after
measure: changes in (oxygen consumption) VO2 max
timeFrame: Baseline and 12 weeks after
measure: changes in peak VO2
timeFrame: Baseline and 12 weeks after
measure: changes in the diaphragmatic path
timeFrame: Baseline and 12 weeks after
measure: changes in diaphragm thickness
timeFrame: Baseline and 12 weeks after
measure: changes in diaphragmatic shortening
timeFrame: Baseline and 12 weeks after
measure: changes in dyspnea
timeFrame: Baseline and 12 weeks after
Other outcomes:
Locations:
city: Girona
country: Spain
facility: Josep Trueta University Hospital
Study officials:
affiliation: Girona Biomedical Research Institute
name: Gerard Muñoz, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05268562: Ketamine and Kidney Injury in Cardiac Surgery
Official title: Impact of Ketamine Versus Propofol for Anesthetic Induction on Acute Kidney Injury and Renal Biomarkers in Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Cardiac Surgery
Keywords: Cardiopulmonary bypass
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2022-03-07
Enrollment: 200
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to investigate the affects of ketamine use for anesthesia at the beginning of heart surgery on kidneys compared to the use of propofol.


Eligibility criteria: Inclusion Criteria:

* Presenting for cardiac surgery at the Mayo Clinic in Rochester, Minnesota.
* Scheduled to undergo complex cardiac surgery with the use of cardiopulmonary bypass. Complex cardiac surgery will be defined as surgery involving more than one heart valve, redo-sternotomy procedures, or combined valvular and coronary artery bypass graft procedures (aortic repair not excluded if meets other criteria).

Exclusion Criteria:

* Left or right ventricular assist device implantation or explantation.
* Procedures not requiring cardiopulmonary bypass.
* Active infection or sepsis requiring antimicrobial therapy and/or vasopressor therapy (treated endocarditis is not excluded).
* Severe hepatic disease resulting in ascites.
* Pre-operative significant renal dysfunction including a baseline creatinine equal to or greater than 2 mg/dL or requiring dialysis.
* Immunosuppressive medication use (including current IV or oral steroids use, use of anti-rejection medications for transplant within 1 month, or chemotherapy within 6 months).
* Immunodeficiency syndrome including HIV/AIDS, leukemia, and multiple myeloma

Primary outcomes:
measure: Acute Kidney Injury
timeFrame: Immediately postop up to 10 days postoperatively
Secondary outcomes:
measure: Vasopressor use
timeFrame: Immediately post induction up to 30 minute following induction
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Erica D Wittwer, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01017562: Differentiation of Aseptic From Septic Loosening by 18F-fluoride PET
Official title: Differentiation of Aseptic From Septic Loosening in Patients With Total Hip Arthroplasty Using 18F-fluoride PET
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hip Arthroplasty
Keywords: To clarify the 18F-fluoride uptake patterns associated with aseptic or septic loosening
Lead sponsor: Yokohama City University Medical Center
Sponsor class: OTHER
First posted: 2009-11-20
Enrollment: 61
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients after total hip arthroplasty who agreed with the informed consent for this study.

Brief summary: In this study, the investigators utilized the 18F-fluoride PET method to evaluate THA cases with a stable, septic or septic loosened implant in order to differentiate these clinical settings using a novel uptake type classification approach.


Eligibility criteria: Exclusion Criteria:

* Within one year after surgery

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Yokohama
country: Japan
facility: Departement of orthopaedic sugery
state: Kanagawa
Study officials:
affiliation: Department of orthopaedic surgey, Yokohama City University
name: Naomi Kobayashi, MD, PhD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03089762: Intra-articular Injection in the Knee of Adipose Derived Stromal Cells and Platelet Rich Plasma for Osteoarthritis
Official title: Intra-articular Injection in the Knee of Adipose Derived Stromal Cells and Platelet Rich Plasma for Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Osteoarthritis
Lead sponsor: Bioheart, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Anupam Hospital
name: RegennMed Research and Therapeutics Delhi
First posted: 2017-03-24
Enrollment: 10
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Stromal vascular fraction (SVF) can easily be obtained from a mini-lipoaspirate procedure of fat tissue and platelet rich plasma (PRP) can be obtained from peripheral blood. Evaluated the safety and preliminary efficacy of administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2.


Eligibility criteria: Inclusion Criteria:

* patients age 50 or older who present with symptomatic primary osteoarthritis of the knee
* daily pain for the previous 3 months
* analgesics usage at least once a week
* less than 30 minutes of morning stiffness
* WOMAC score of ≤ 75 in the target knee
* Brandt Radiographic Grading Scale of Osteoarthritis grade 1 and 2

Exclusion Criteria:

* evidence of secondary knee osteoarthritis
* severe osteoarthritis (Joint space width - JSW \< 2 mm)
* prior intra articular injections within the previous one year prior to inclusion
* patients with clinically significant systemic disease

Primary outcomes:
measure: WOMAC (Western Ontario and McMaster Universities Arthritis Index)
timeFrame: 1 year
Secondary outcomes:
measure: Six minute walk distance
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
citation: Bansal H, Comella K, Leon J, Verma P, Agrawal D, Koka P, Ichim T. Intra-articular injection in the knee of adipose derived stromal cells (stromal vascular fraction) and platelet rich plasma for osteoarthritis. J Transl Med. 2017 Jun 19;15(1):141. doi: 10.1186/s12967-017-1242-4.
Clinical trial NCT03958162: The Comparison of Uniportal and Tubeless Video Assisted Thoracic Surgery and Transbronchial Lung Cryobiopsy in the Diagnosis of Interstitial Lung Disease
Official title: The Comparison of Uniportal and Tubeless Video Assisted Thoracic Surgery and Transbronchial Lung Cryobiopsy Within the Multidisciplinary Discussion Context in the Diagnosis of Interstitial Lung Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Surgical Lung Biopsy
Transbronchial Lung Cryobiopsy
Interstitial Lung Disease
Keywords: surgical lung biopsy
transbronchial lung cryobiopsy
interstitial lung disease
Lead sponsor: Guangzhou Institute of Respiratory Disease
Sponsor class: OTHER
First posted: 2019-05-21
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: To compariing the uniportal and tubeless video assisted thoracic surgery and trnsbronchial lung cryobiopsy within the multidisciplinary discussion context in the diagnosis of interstitial lung disease，and assess the safety and cost-effectiveness. This is a prospective control trial.


Eligibility criteria: Inclusion Criteria:

1. 18 yrs ≤ age\<75yrs
2. Patients diagnosed as interstitial lung disease with comprehensive clinical data (including history, serological test, spirometry test and high resolution computed tomography)
3. Further pathological data was still required after multidisciplinary discussion.

Exclusion Criteria:

1. Severe pulmonary dysfunction: forced vital capacity (FVC) ≤65% or carbon-monoxide diffusion coefficient (DLco) ≤45% of predicted value
2. Pulmonary hypertension: An estimated systolic pulmonary artery pressure\>50mmHg on echocardiography
3. Abnormal coagulation parameters or thrombocytopenia (\<50\*109/L)
4. Severe comorbidities leading to inoperable condition
5. Patients cannot give consent or refuse biopsy

Primary outcomes:
measure: Diagnotic yield
timeFrame: two weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01917162: Multi-Center Clinical Evaluation of Two Daily Disposable Contact Lenses (Study 2)
Official title: Multi-Center Clinical Evaluation of Two Daily Disposable Contact Lenses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Refractive Error
Keywords: contact lenses
daily disposable contact lenses
silicone hydrogel
contact lens comfort
near-sighted
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2013-08-06
Enrollment: 86
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the subjective performance of two daily disposable contact lenses with respect to comfort and handling.


Eligibility criteria: Inclusion Criteria:

* Adapted soft contact lens wearer;
* Spherical distance contact lens prescription between -1.00 and -6.00 diopter (inclusive);
* Spectacle cylinder ≤0.75 diopter in the least astigmatic eye, ≤1.00 diopter in the other;
* Correctable to 6/9 (20/30) in both eyes;
* Read, understand, and sign the informed consent;
* Willing to comply with the wear schedule;
* Willing to comply with the study visit schedule;
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Any active corneal infection, injury or inflammation;
* Systemic or ocular allergies which might interfere with contact lens wear;
* Systemic or ocular disease which might interfere with contact lens wear;
* Strabismus or amblyopia;
* Corneal refractive surgery and any anterior segment surgery;
* Use of systemic/topical medication contraindicating contact lens wear;
* Use of gas permeable contact lenses within 1 month preceding the study;
* Participation in any concurrent clinical trial or in the last 30 days;
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Initial comfort
timeFrame: Baseline
Secondary outcomes:
measure: End of Day Comfort
timeFrame: Day 7
measure: Overall Comfort
timeFrame: Day 7
measure: Overall Handling at Time of Removal
timeFrame: Day 7
Other outcomes:
Locations:
city: Farnham
country: United Kingdom
facility: Visioncare Research Ltd
state: Surrey
Study officials:
affiliation: Alcon Research
name: Joachim Nick, Dipl. Ing.
role: STUDY_DIRECTOR
References:
Clinical trial NCT03080662: Impact of Inspiratory Muscle Training on Daily Physical Activity (INAF)
Official title: Impact of Inspiratory Muscle Training on Daily Physical Activity (INAF)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Inspiratory Muscle Training
Lead sponsor: Parc de Salut Mar
Sponsor class: OTHER
First posted: 2017-03-15
Enrollment: 20
Sex: ALL
Minimum age (years): 45
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The impact of the reduction of daily physical activity (DPA) in patients with COPD (chronic obstructive pulmonary disease) is a highly studied area, due to its impact on the quality of life and the clinical evolution of the disease . This fact has multifactorial components: its function is naturally diminished with time, and its effects on the loss of physical condition (decondition). However, dynamic hyperinflation and respiratory muscular dysfunction, especially in patients with more symptomatology, have been identified as those that have the most relevant factors that impact on daily physical activity Due to the detrimental effects of the pulmonary hyperinflation, the diaphragm is flatter and shorter, being in a position of mechanical disadvantage. This contributes to a reduced effort capacity and increase in the dyspnea of patients during daily activities.

Resistance training improves their exercise capacity and reduces dyspnea, however it does not improve inspiratory muscle strength. It is for this reason, that specific training of the inspiratory muscles, offers special interest in patients with decreased inspiratory muscle strength and pulmonary hyperinflation.


Eligibility criteria: Inclusion Criteria:

* To be eligible for the respiratory rehabilitation programme participants must have stable COPD (at least 4 weeks), inspiratory muscle weakness (PImax \<70%) and pulmonary hyperinflation (TLC \> 120%). Patient that have signed inform consent.

Exclusion Criteria:

* Hospitalization within the previous 14 days
* Current participation in rehabilitation program,
* Locomotor or neurological condition or disability limiting the ability to perform exercise,
* Lung transplantation or lung volume reduction surgery foreseen within 1 month after discharge.

Primary outcomes:
measure: improvement of daily physical activity
timeFrame: Baseline and 5 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Del Mar
Study officials:
References:
Clinical trial NCT01468662: CMR Repeatability in STEMI
Official title: Cardiovascular Magnetic Resonance Scan Repeatability in ST Segment Elevation Myocardial Infarction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: STEMI
Lead sponsor: University of Bristol
Sponsor class: OTHER
First posted: 2011-11-09
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: ST segment elevation myocardial infarction

Brief summary: The investigators propose to conduct a study to measure the reproducibility of CMR parameters that have been used to predict outcome following PPCI: infarct size, left ventricular volumes, myocardial salvage, microvascular obstruction (MVO) and myocardial oedema.


Eligibility criteria: Inclusion Criteria:

Participant may enter study if ALL of the following apply

1. ST segment myocardial infarction as defined by ECG (by 2 contiguous limb leads with \>1 mm ST-segment elevation, or \>2 mm ST-segment elevation in contiguous precordial leads, or new LBBB) and \> 20 minutes of cardiac chest pain
2. Written informed consent

Exclusion Criteria:

Participant may not enter study if ANY of the following apply

1. Contraindication to MRI (implanted pacemaker/ defibrillator, ferromagnetic metal implant/ injury, claustrophobia, obesity/ too large for CMR scanner)
2. Known allergy to gadolinium
3. Chronic atrial fibrillation
4. Renal impairment with eGFR \<30
5. Cardiogenic shock
6. Patients with special communication needs

Primary outcomes:
measure: Inter-observer, intra-observer and inter-scan variability and agreement
timeFrame: Between 2 scans
Secondary outcomes:
Other outcomes:
Locations:
city: Bristol
country: United Kingdom
facility: Bristol Heart Institute
Study officials:
affiliation: University of Bristol
name: Elisa McAlindon, BMBS
role: PRINCIPAL_INVESTIGATOR
References:
citation: McAlindon EJ, Pufulete M, Harris JM, Lawton CB, Moon JC, Manghat N, Hamilton MC, Weale PJ, Bucciarelli-Ducci C. Measurement of myocardium at risk with cardiovascular MR: comparison of techniques for edema imaging. Radiology. 2015 Apr;275(1):61-70. doi: 10.1148/radiol.14131980. Epub 2014 Oct 21.
Clinical trial NCT01506180: In-Hospital Comprehensive Geriatric Assessment in Aged Acute Medical Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Disease
Keywords: acute medical care
comprehensive geriatric assessment
Health Services for the Aged
Geriatric Assessment
Geriatrics
Aged
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2012-01-09
Enrollment: 3877
Sex: ALL
Minimum age (years): 80
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Acute medical patients aged 80 years or older

Brief summary: The purpose of this study is to compare acute ill elderly medical patients in a geriatric department with general medical departments, and to examine the effects of comprehensive geriatric assessment in the geriatric setting compared with general medical care.

Detailed description: Design:

1) a cross-sectional study followed by 2) a subgroup study by retrospective follow-up

Eligibility criteria: Inclusion Criteria:

* patients admitted to the departments of medicine at Aarhus University Hospital either through the emergency medical ward or directly to the medical wards in the period from January 1, 2009 to December 31, 2010.

Exclusion Criteria:

* patients admitted to the neurology-, cardiology-, nephrology- or haematology departments, and patients discharged directly to their homes from the emergency medical ward.

Primary outcomes:
measure: Comorbidity
timeFrame: At hospital admission (day 1)
measure: Length of hospital stay
timeFrame: Number of days of hospitalization an expected average of 8 days
Secondary outcomes:
measure: Acute readmission
timeFrame: 30 days and 90 days
measure: Mortality
timeFrame: Within 30 days after hospital admission
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
state: Central Denmark Region
Study officials:
References:
citation: Gregersen M, Pedersen AB, Damsgaard EM. Comprehensive geriatric assessment increases 30-day survival in the aged acute medical inpatients. Dan Med J. 2012 Jun;59(6):A4442.
Clinical trial NCT03388580: Predictors for Bronchoalveolar Lavage (BAL) Recovery Rate Derived From Quantified Computed Tomography (qCT)
Official title: Predictors for Bronchoalveolar Lavage Recovery Rate Derived From Quantified Computed Tomography
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Interstitial Lung Disease
Pneumonia
Malignant Neoplasm
Lead sponsor: Universitätsmedizin Mannheim
Sponsor class: OTHER
First posted: 2018-01-03
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing elective BAL with clinical indication.

Brief summary: Bronchoalveolar lavage (BAL) is an important diagnostic method. The percentage of fluid extracted after instillation (recovery rate) is crucial for following diagnostic tests. The investigators aimed to compare novel quantified airway parameters from pre-interventional lung computed tomography (CT) with recovery rates to find possible predictive markers.


Eligibility criteria: Inclusion Criteria:

* retrospective analysis of all patients undergoing BAL and complete documentation

Exclusion Criteria:

* incomplete documentation

Primary outcomes:
measure: recovery rate
timeFrame: 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: